POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS

This is a first-in-human study to test the safety and find the right dose of an experimental oral drug called PRT12396 for people with certain rare blood cancers. It will enroll about 100 adults with high-risk polycythemia vera or myelofibrosis. The main goal is to see how well t…

This study is testing whether canakinumab, an anti-inflammatory injection given every 3 weeks, can help control myelofibrosis. Researchers want to see if it reduces symptoms like fatigue and enlarged spleen, improves anemia, and is safe for patients. The trial is for adults with …

This early-stage trial is testing a new oral medication called AJ1-11095 for adults with myelofibrosis, a serious bone marrow cancer. The study is for patients whose disease didn't respond well to or came back after standard JAK2 inhibitor treatment. Researchers will determine th…

This study continues treatment for 400 people with rare blood cancers who are already benefiting from the drug bomedemstat in earlier trials. Its main goal is to collect long-term safety information and see how well the drug continues to control the disease over time. The study i…

This study is testing an experimental drug called DISC-0974 in people with myelofibrosis or myelodysplastic syndrome who have anemia. The main goals are to see if the drug is safe and if it can help improve red blood cell counts, potentially reducing or eliminating the need for b…

This study is testing an investigational drug called pacritinib against standard care treatments for adults with myelofibrosis, a serious bone marrow cancer, who also have dangerously low platelet counts. The main goals are to see if pacritinib can reduce spleen size and ease dis…

This is a long-term observational study aiming to better understand a group of rare, chronic blood cancers called myeloproliferative neoplasms (MPNs). It will follow 5,000 adults in the U.S. who have been diagnosed with an MPN for at least five years, collecting information from …